Windward Bio targets near-$1bn valuation in US IPO
The Novo-backed Swiss drug developer is seeking about $175 million in a Nasdaq offering as its lead asthma treatment advances through late-stage trials.

Windward Bio, a Novo-backed Swiss drug developer, is targeting a valuation of about $1 billion in a US initial public offering, seeking public-market capital as its lead respiratory treatment moves through late-stage clinical development.
The Basel-based company is offering 10.29 million shares at $16 to $18 each, according to IPOScoop’s account of its November 9, 2026 amended registration filing. At the $17 midpoint, the offering would raise $174.93 million and, together with a concurrent private placement, give Windward a market capitalisation of $986.66 million.
The proposed listing is on Nasdaq, with WWB as the proposed ticker. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are joint bookrunners. The terms remain proposed: neither the final offer price nor completed proceeds are established by the supplied reporting.
A US capital-markets move
For Windward, the American move is principally about financing rather than a disclosed factory, office or commercial launch. A Nasdaq flotation would bring the Swiss company’s clinical pipeline to US public investors while it faces several years of trials before key late-stage results are expected.
Windward is developing ultra-long-acting antibody medicines for asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Its leading candidates target thymic stromal lymphopoietin, known as TSLP, which the prospectus describes as acting upstream of multiple inflammatory pathways and as a clinically validated target in respiratory disease.
The company’s proposed differentiation rests on how long its medicines could work between doses and, for one candidate, on targeting two inflammatory pathways at once. Those are development propositions rather than established commercial advantages: the treatments described in the filing remain in clinical studies.
Lead asthma programme advances
Windward’s lead candidate, WIN378, is an anti-TSLP monoclonal antibody being developed for asthma and COPD. It licensed rights from Sichuan Kelun-Biotech Biopharmaceutical and Harbour BioMed covering the world excluding Greater China and certain Asian countries.
Following a planned interim analysis of the Phase 2 portion of its POLARIS-1 study in severe, uncontrolled asthma, Windward began the Phase 3 portion in September 2026. Topline results are expected in the first half of 2029, according to the prospectus excerpts published by IPOScoop.
A second Phase 3 asthma study, POLARIS-2, is planned to begin recruiting patients in the first half of 2027, also with topline results expected in the first half of 2029. A separate Phase 2 COPD study, SIRIUS, began in June 2026 and is expected to report topline results in the second half of 2027.
Windward reported that Phase 1 findings for WIN378 showed an extended half-life supporting twice-yearly injections under the skin, a low rate of antidrug antibodies and no observed treatment-related serious adverse events. These early findings do not establish the outcome of the larger efficacy studies.
A second candidate and a longer funding horizon
Its second leading candidate, WIN027, is a bispecific antibody targeting both TSLP and interleukin-13. It is in a Phase 1 healthy-volunteer study, with investigational new drug applications open in the United States, Australia and China—giving Windward a US regulatory connection alongside the proposed listing.
Windward plans to begin recruitment for global WIN027 studies in COPD and atopic dermatitis in the first half of 2027. Full Phase 1 pharmacokinetic and immunogenicity data are also expected in that period.
The company reported a net loss of $68.21 million for the 12 months ended June 30, 2026, according to the financial statements cited by IPOScoop. The IPO would therefore come during a loss-making development phase, with investors weighing the potential of less frequent dosing against clinical execution risk and a timetable stretching into 2029.


